Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15,685 | $31,002 | $25,851 | $79,163 |
| - Cash | $3,857 | $4,092 | $5,396 | $44,443 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $11,828 | $26,910 | $20,455 | $34,719 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$83,891 | $4,910 | -$161,247 | -$125,702 |
| % Margin | – | – | – | – |
| Net Income | -$79,979 | -$98,792 | -$157,043 | -$125,752 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.65 | -3.28 | -5.3 | -7.16 |
| % Growth | 19.2% | 38.1% | 26% | – |
| Operating Cash Flow | -$51,756 | -$51,659 | -$103,802 | -$91,873 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$51,756 | -$51,659 | -$103,802 | -$91,873 |